Topics: Immunology IBD Quiz
Which of the following was NOT a key finding from the UNIFI induction study of Ustekinumab in UC?
A. Symptomatic improvement observed as early as Week 2
B. Clinical response in ~80% of patients at Week 16
C. CS-free remission in ~80% of patients at Week 24
Preview next quiz:
What were the treatment arms, and their duration, for the UNITI-1 and UNITI-2 induction studies?
A. Ustekinumab ~6 mg/kg or 130 mg, versus adalimumab over a 12-week period
B. Ustekinumab ~3 mg/kg or 220 mg versus vedolizumab over an 8-week period
C. Ustekinumab ~6 mg/kg or 130 mg, versus placebo over an 8-week period
D. Ustekinumab ~4 mg/kg versus adalimumab and placebo over a 12-week period